Low-dose diet supplement of a natural flavonoid, luteolin, ameliorates diet-induced obesity and insulin resistance in mice

Molecular Nutrition and Food Research

Volumn 58, Issue 6, 2014, Pages 1258-1268

  Xu, Na ^a,b   Zhang, Lei ^a   Dong, Jing ^a   Zhang, Xian ^a   Chen, Yan Guang ^a   Bao, Bin ^a   Liu, Jian ^a  

^a HEFEI UNIVERSITY OF TECHNOLOGY   (China)

^b ANHUI SCIENCE AND TECHNOLOGY UNIVERSITY   (China)

Author keywords

Angiogenesis; Insulin resistance; Luteolin; Mast cells; Obesity

Indexed keywords

CATHEPSIN; INTERLEUKIN 6; LUTEOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL; APOPTOSIS; BONE MARROW CELL; C57BL MOUSE; DIET SUPPLEMENTATION; DOWN REGULATION; DRUG EFFECTS; GENETICS; INFLAMMATION; INSULIN RESISTANCE; LIPID DIET; MALE; MAST CELL; METABOLISM; MOUSE; OBESITY; SIGNAL TRANSDUCTION; WEIGHT GAIN;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; APOPTOSIS; BONE MARROW CELLS; CATHEPSINS; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; DOWN-REGULATION; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; LUTEOLIN; MALE; MAST CELLS; MICE; MICE, INBRED C57BL; OBESITY; PPAR GAMMA; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT GAIN;

EID: 84901944300     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300830     Document Type: Article

References (51)

1. Lijnen, H. R., Angiogenesis and obesity. Cardiovasc. Res. 2008, 78, 286-293.
2. Cao, Y., Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat. Rev. Drug Discov. 2010, 9, 107-115.
3. Liu, J., Divoux, A., Sun, J., Zhang, J. et al., Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat. Med. 2009, 15, 940-945.
4. Reynolds, J. E. F., Prasad, A. B. (Eds.), Martindale-The Extra Pharmacopoeia, The Pharmaceutical Press, London 1982, 1448 p.
5. McEvoy, G. K. (Ed.), American Hospital Formulary Service-Drug Information, American Society of Health-System Pharmacists, Bethesda 1996, 2719 p.
6. Okayama, Y., Benyon, R. C., Rees, P. H., Lowman, M. A. et al., Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine. Clin. Exp. Allergy 1992, 22, 401-409.
7. Klooker, T. K., Braak, B., Koopman, K. E., Welting, O. et al., The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010, 59, 1213-1221.
8. Lopez-Lazaro, M., Distribution and biological activities of the flavonoid luteolin. Mini Rev. Med. Chem. 2009, 9, 31-59.
9. Kempuraj, D., Tagen, M., Iliopoulou, B. P., Clemons, A. et al., Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells. Br. J. Pharmacol. 2008, 155, 1076-1084.
10. Kimata, M., Shichijo, M., Miura, T., Serizawa, I. et al., Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin. Exp. Allergy 2000, 30, 501-508.
11. Bagli, E., Stefaniotou, M., Morbidelli, L., Ziche, M. et al., Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3′-kinase activity. Cancer Res. 2004, 64, 7936-7946.
12. Kim, J. H., Lee, E. O., Lee, H. J., Ku, J. S. et al., Caspase activation and extracellular signal-regulated kinase/Akt inhibition were involved in luteolin-induced apoptosis in Lewis lung carcinoma cells. Ann. N. Y. Acad. Sci. 2006, 1090, 147-160.
13. Karrasch, T., Kim, J. S., Jang, B. I., Jobin, C., The flavonoid luteolin worsens chemical-induced colitis in NF-kappaB(EGFP) transgenic mice through blockade of NF-kappaB-dependent protective molecules. PloS One 2007, 2, e596.
14. Ando, C., Takahashi, N., Hirai, S., Nishimura, K. et al., Luteolin, a food-derived flavonoid, suppresses adipocyte-dependent activation of macrophages by inhibiting JNK activation. FEBS Lett. 2009, 583, 3649-3654.
15. Deqiu, Z., Kang, L., Jiali, Y., Baolin, L. et al., Luteolin inhibits inflammatory response and improves insulin sensitivity in the endothelium. Biochimie 2011, 93, 506-512.
16. Zhang, J., Sun, J., Lindholt, J. S., Sukhova, G. K. et al., Mast cell tryptase deficiency attenuates mouse abdominal aortic aneurysm formation. Circ. Res. 2011, 108, 1316-1327.
17. Leto, D., Saltiel, A. R., Regulation of glucose transport by insulin: traffic control of GLUT4. Nat. Rev. Mol. Cell Biol. 2012, 13, 383-396.
18. Rupnick, M. A., Panigrahy, D., Zhang, C. Y., Dallabrida, S. M. et al., Adipose tissue mass can be regulated through the vasculature. Proc. Natl. Acad. Sci. USA 2002, 99, 10730-10735.
19. Sato, K., Tsuchihara, K., Fujii, S., Sugiyama, M. et al., Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Res. 2007, 67, 9677-9684.
20. Yang, M., Zhang, Y., Pan, J., Sun, J. et al., Cathepsin L activity controls adipogenesis and glucose tolerance. Nat. Cell Biol. 2007, 9, 970-977.
21. Yang, M., Sun, J., Zhang, T., Liu, J. et al., Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism in mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 2202-2208.
22. Shi, G. P., Sukhova, G. K., Kuzuya, M., Ye, Q. et al., Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ. Res. 2003, 92, 493-500.
23. Wang, B., Sun, J., Kitamoto, S., Yang, M. et al., Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J. Biol. Chem. 2006, 281, 6020-6029.
24. Osborn, O., Olefsky, J. M., The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 2012, 18, 363-374.
25. Olefsky, J. M., Glass, C. K., Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 2010, 72, 219-246.
26. Ouchi, N., Parker, J. L., Lugus, J. J., Walsh, K., Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11, 85-97.
27. Sismanopoulos, N., Delivanis, D. A., Alysandratos, K. D., Angelidou, A. et al., Mast cells in allergic and inflammatory diseases. Curr. Pharm. Des. 2012, 18, 2261-2277.
28. Sun, J., Sukhova, G. K., Wolters, P. J., Yang, M. et al., Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat. Med. 2007, 13, 719-724.
29. Sun, J., Sukhova, G. K., Yang, M., Wolters, P. J. et al., Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J. Clin. Invest. 2007, 117, 3359-3368.
30. Baumgartner, R. A., Yamada, K., Deramo, V. A., Beaven, M. A., Secretion of TNF from a rat mast cell line is a brefeldin A-sensitive and a calcium/protein kinase C-regulated process. J. Immunol. 1994, 153, 2609-2617.
31. Kandere-Grzybowska, K., Kempuraj, D., Cao, J., Cetrulo, C. L. et al., Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin. Br. J. Pharmacol. 2006, 148, 208-215.
32. Rottem, M., Mekori, Y. A., Mast cells and autoimmunity. Autoimmun. Rev. 2005, 4, 21-27.
33. Kinet, J. P., The essential role of mast cells in orchestrating inflammation. Immunol. Rev. 2007, 217, 5-7.
34. Artuc, M., Hermes, B., Steckelings, U. M., Grutzkau, A. et al., Mast cells and their mediators in cutaneous wound healing-active participants or innocent bystanders? Exp. Dermatol. 1999, 8, 1-16.
35. Crivellato, E., Nico, B., Ribatti, D., Mast cells and tumour angiogenesis: new insight from experimental carcinogenesis. Cancer Lett. 2008, 269, 1-6.
36. Nechushtan, H., The complexity of the complicity of mast cells in cancer. Int. J. Biochem. Cell Biol. 2010, 42, 551-554.
37. Moon, T. C., St. Laurent, C. D., Morris, K. E., Marcet, C. et al., Advances in mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol. 2010, 3, 111-128.
38. Chmelar, J., Chung, K. J., Chavakis, T., The role of innate immune cells in obese adipose tissue inflammation and development of insulin resistance. Thromb. Haemost. 2013, 109, 399-406.
39. Mueller, M., Lukas, B., Novak, J., Simoncini, T. et al., Oregano: a source for peroxisome proliferator-activated receptor gamma antagonists. J. Agric. Food Chem. 2008, 56, 11621-11630.
40. Puhl, A. C., Bernardes, A., Silveira, R. L., Yuan, J. et al., Mode of peroxisome proliferator-activated receptor gamma activation by luteolin. Mol. Pharmacol. 2012, 81, 788-799.
41. Ding, L., Jin, D., Chen, X., Luteolin enhances insulin sensitivity via activation of PPARgamma transcriptional activity in adipocytes. J. Nutr. Biochem. 2010, 21, 941-947.
42. Jang, S., Kelley, K. W., Johnson, R. W., Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc. Natl. Acad. Sci. USA 2008, 105, 7534-7539.
43. Lee, J. K., Kim, S. Y., Kim, Y. S., Lee, W. H. et al., Suppression of the TRIF-dependent signaling pathway of Toll-like receptors by luteolin. Biochem. Pharmacol. 2009, 77, 1391-1400.
44. Park, C. M., Jin, K. S., Lee, Y. W., Song, Y. S., Luteolin and chicoric acid synergistically inhibited inflammatory responses via inactivation of PI3K-Akt pathway and impairment of NF-kappaB translocation in LPS stimulated RAW 264.7 cells. Eur. J. Pharmacol. 2011, 660, 454-459.
45. Shao, L., Liu, K., Huang, F., Guo, X. et al., Opposite effects of quercetin, luteolin, and epigallocatechin gallate on insulin sensitivity under normal and inflammatory conditions in mice. Inflammation 2013, 36, 1-14.
46. Gordon, J. R., Galli, S. J., Release of both preformed and newly synthesized tumor necrosis factor alpha (TNF-alpha)/cachectin by mouse mast cells stimulated via the Fc epsilon RI. A mechanism for the sustained action of mast cell-derived TNF-alpha during IgE-dependent biological responses. J. Exp. Med. 1991, 174, 103-107.
47. Grutzkau, A., Kruger-Krasagakes, S., Baumeister, H., Schwarz, C. et al., Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol. Biol. Cell 1998, 9, 875-884.
48. Metcalfe, D. D., Mast cells and mastocytosis. Blood 2008, 112, 946-956.
49. Sugiyama, H., Nonaka, T., Kishimoto, T., Komoriya, K. et al., Peroxisome proliferator-activated receptors are expressed in mouse bone marrow-derived mast cells. FEBS Lett. 2000, 467, 259-262.
50. Sugiyama, H., Nonaka, T., Kishimoto, T., Komoriya, K. et al., Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation. Eur. J. Immunol. 2000, 30, 3363-3370.
51. Kim, J. E., Son, J. E., Jang, Y. J., Lee, D. E. et al., Luteolin, a novel natural inhibitor of tumor progression locus 2 serine/threonine kinase, inhibits tumor necrosis factor-alpha-induced cyclooxygenase-2 expression in JB6 mouse epidermis cells. J. Pharmacol. Exp. Ther. 2011, 338, 1013-1022.